Reuters logo
BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY
June 5, 2017 / 5:02 PM / 6 months ago

BRIEF-AGENUS' ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

June 5 (Reuters) - Agenus Inc

* AGENUS’ ANTI-CTLA-4 ANTIBODY SHOWS STRONG SAFETY AND TOLERABILITY

* ‍ANNOUNCED RESULTS FROM AN ONGOING PHASE 1 DOSE-ESCALATION TRIAL FOR ITS ANTI-CTLA-4 ANTIBODY, AGEN1884​

* ‍CONTINUE TO ADVANCE ANTI-CTLA-4 ANTIBODY TRIAL, ANTIBODY IS WELL TOLERATED​

* “WHILE SYMPTOMS ASSOCIATED WITH IMMUNE-RELATED ADVERSE EVENTS WERE PRESENT” IN STUDY, “THERE WERE NO DOSE-LIMITING TOXICITIES REPORTED TO DATE” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below